Novo Nordisk A/S (NVO) Expands Manufacturing to Support Rising Global Demand for GLP-1 Drugs

On March 2, Novo Nordisk A/S (NYSE:NVO) reiterated its plans to invest about $506 million to expand its manufacturing facility in Ireland. The investment will finance the expansion of production capacity for oral products, including various formulations of GLP-1 drugs.

The expansion is also part of an effort to meet current and future demand outside the US. Construction of the manufacturing facility in Athlone, Ireland, has already begun. Completion is slated to happen gradually between 2027 and 2028.

Novo Nordisk has enjoyed a first-mover advantage in the obesity market with the launch of GLP-1 drugs sold as Ozempic and Wegovy for years. The expansion drive comes after the company misjudged demand for the drugs. Semaglutide has been in short supply, forcing some marketers to sell cheaper copycat versions of the drug. This has weighed significantly on the company’s sales.

The company has indicated that it has a sufficient supply of Wegovy pills to meet US demand. The manufacturing expansion confirms plans to introduce the pill in additional markets.

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company that develops, manufactures, and markets medicines for serious chronic diseases. It is a leader in diabetes care (including insulin and Ozempic), obesity management (Wegovy), haemophilia care, and rare endocrine disorders.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Best Gold Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.